Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nabi-HB Intravenous
- Development stage
- Discontinued
- Lead developer
- Vaxart
- Modality
- Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Nabi-HB Intravenous (investigated during development under the brand name Civacir) is an intravenous formulation of human hepatitis B immune globulin (HBIG) that was developed for the prevention of hepatitis B virus (HBV) recurrence in patients undergoing liver transplantation. It is a sterile solution of purified polyclonal immunoglobulin G (IgG) containing high titers of antibodies directed against the hepatitis B surface antigen (HBsAg). The mechanism of action involves passive immunization, where the exogenous antibodies bind to and neutralize circulating HBV particles, thereby preventing the infection of the newly transplanted liver. Originally developed by Nabi Biopharmaceuticals, the product reached Phase 3 clinical trials but was ultimately discontinued and never brought to market. It is a specialized intravenous version of the intramuscular Nabi-HB product, which remains FDA-approved for post-exposure prophylaxis.
- Brand names
- Civacir
- Other names
- Nabi-HB IntravenousHepatitis B Immune Globulin (Human) IntravenousHBIG IV
02
Targets
HBsAg (Hepatitis B surface antigen)
Beyond the preview
Go deeper on Nabi-HB Intravenous.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nabi-HB Intravenous.